Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting
FLORHAM PARK, N.J., April 4, 2023 — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro.
Oral and Poster Presentation
- Title: Decellularized Dehydrated Human Amniotic Membranes Support the Cellular Functions of Human Tenocytes in Vitro
- Abstract number: TBD
- Session: Bioactive materials for hard and/or soft tissue regeneration
- Presenter: Anna Gosiewska, Ph.D., Vice President Research & Development, Degenerative Diseases, Celularity Inc.
- Location: Sheraton San Diego Hotel and Marina, San Diego, CA
- Date and Time: April 19, 2023 3:45-4:00pm; Presentation Slot: 5
- Poster Session: Poster Session 1 (P1) April 19, 2023; Poster Session 2 (P2), April 20, 2023 and Poster Session 3 (P3) April 21, 2023.
“We look forward to the upcoming SFB annual meeting and presenting our most current biomaterials research,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “Celularity’s unique technology platform is grounded in our use of the post-partum placenta as the source of cells and biomaterials for the development of therapeutics. This creates two independent but complimentary product opportunities in cellular and regenerative medicine, which reinforces our confidence in potential therapeutic benefits of biomaterials as we advance the development of these therapeutic options for patients,” said Hariri.
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. These therapeutic programs target indications in autoimmune, infectious and degenerative diseases, and cancer. In addition, Celularity develops, manufactures, and commercializes innovative biomaterial products also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
To learn more, visit celularity.com
Celularity Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding Celularity’s ability to advance its cellular and regenerative medicine candidates in clinical development in cancer, immunological and degenerative diseases; among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel biomaterial products and cellular therapies, and the clinical trial and regulatory approval process; and risks associated with Celularity’s current liquidity, as well as developments relating to Celularity’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. These risks and uncertainties may be amplified by current economic situations, including inflation, supply chain issues and overall economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.